Phencyclidine concentrations in postmortem body fluids and tissues

Phencyclidine (PCP) concentrations have been studied in the blood and tissues of Los Angeles County victims whose deaths were related to PCP use. In most cases PCP blood concentrations ranged from 0.01 to 0.9 micrograms/mL while higher concentrations were found in the liver, urine, bile, brain, and kidney.

An analysis on the equivalence of the eye to a system with aberration

Computed transfer functions for epsilon = 0.60 and 0.75 annular pupils of 2.67 mm o.d. show that absorption of the average spherical aberration of the eye is still incomplete but if the eye is so designed as to adjust its focal plane in order to achieve a best Strehl ratio, it would show a transfer function approaching that of a diffraction limited system, i.e. the optical defect of the eye is overcompensated. However, it is argued that a varying amount of focusing adjustment of the eye is needed in order to account for the transfer function of the eye of different pupil sizes, though not always to the extent of achieving a best Strehl ratio. Such a property of the eye is referred to variously as the antidefocusing, deblurring or contrast constancy phenomenon and, when operationally defined, this is equivalent to saying that the eye has a greater depth of focus than that defined for a physical system based upon a fixed demodulation criterion. The significance of the physiological depth of the eye is discussed.

A method for the separation and determination of neutral compounds in postmortem tissues

A convenient method for the extraction of neutral drugs in necrotic tissues is described. The procedure includes the use of hot dilute acid for isolating neutrals from tissue extract residues and of internal standard to facilitate quantitative and recovery measurement of the drugs by gas chromatography. The recovery of seven neutral compounds from liver ranged from 47.0% to 89.3%. The limit of detection of these drugs were 0.5 to 1.0 mg/kg.

A new mouse cell-surface antigen (Ly-m18) defined by a monoclonal antibody

Spleen cells from C3H/An mice immunized with spleen cells of C57BL/6-H-2k mice were fused with myeloma cell line NS.1. One established hybrid cell line continuously secreted antibody that recognized a new surface antigen provisionally called Ly-m18. The new alloantigen is expressed on 90 percent of thymus cells, 55 percent of spleen cells, and 45 percent of either lymph-node or bone-marrow cells. It is also expressed on cells derived from brain, kidney, and liver. Fifty percent of either peripheral T or B cells express the Ly-m18 antigen, and some tumor cell lines with T, B, pre-B or stem cell characteristics are Ly-m18 (+). The strain distribution pattern distinguishes Ly-m18 antigen from all other murine lymphocyte alloantigens. The typing data of two sets of CXB and AKXL recombinant inbred strains indicate that the Ly-m18 gene is linked to the Ltw-2 locus which has not yet been assigned to a chromosome.

A new mouse cell-surface antigen (Ly-m20) controlled by a gene linked to Mls locus and defined by monoclonal antibodies

Five monoclonal antibodies were established by the fusion of mouse myeloma cells (NS.1) with spleen cells from A and (A x C3H/An)F1 mice hyperimmunized with 70Z/3 tumor cells. These antibodies recognized a new antigenic specificity provisionally called Ly-m20.2. In direct cytotoxicity assays, 60 percent of cells in spleen, 40 percent in lymph node, 50 percent in bone marrow and less than 5 percent in thymus were found to react with three of the five antibodies, whereas the two others yielded somewhat lower cytotoxicity indices. The Ly-m20.2 antigen was also expressed on cells derived from liver and kidney but not on cells derived from brain. As judged from cytotoxicity assays with separated T and B cells, Ly-m20.2 antigen is carried preferentially on B lymphocytes. Direct plaque-forming cells (PFC) were completely eliminated by Ly-m20.2-specific antibody and complement. Linkage tests by analysis in 20 (CBA/J x C3H/An) x C3H/An backcross mice and by segregation analysis of BXH and SWXL recombinant inbred strains indicate close association of the loci controlling Ly-m20.2 and M1s antigens on chromosome 1.

Ly-m19: the Lyb-2 region of mouse chromosome 4 controls a new surface alloantigen

Spleen cells from an SJL mouse immunized with 70Z/3 cells, an established pre-B cell line, were fused with cells of the nonsecretory myeloma line NS.1. One established hybridoma cell line (clone K10.6) continuously secreted antibody that recognized a new antigenic specificity tentatively named Ly-m19. This newly found antigen is detectable on both T and B cells. Cytotoxicity assays reveal that 75 percent of the spleen and lymph-node cells, 35 percent of bone-marrow cells, and 15 percent of thymus cells reacted with antibody of clone K10.6. Strains expressing the specificity Ly-m19.1 are characterized by negative reactions and include the strains AKR, CE/J, RF/J, GR/A, SJL, P/J, BDP/J, and LG/J. All other strains so far tested are Ly-m19.2. This strain distribution pattern distinguishes Ly-m19 from any known murine lymphocyte alloantigen, but it parallels the Lyb-2c haplotype. Linkage test of a set of AKXL recombinant inbred strains revealed close linkage of Ly-m19 and Lyb-2 loci on mouse chromosome 4.